Bristol-Myers Squibb and Daiichi Sankyo are allying to assess the benefits of a new combination cancer regimen.

The companies will conduct a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and Daiichi Sankyo's investigational antibody drug conjugate DS-8201 in patients with HER2-expressing metastatic breast and urothelial cancers.

“Bristol-Myers Squibb and Daiichi Sankyo are partnering on the development of a new combination cancer regimen.“

The phase Ib study will consist of two parts, with a dose escalation phase determining a possible recommended dosage scheme, while the second part will analyse the efficacy, safety and tolerability of this regimen.

Enrolment will commence during the first quarter of 2018 in the US and Europe, with Daiichi Sankyo to act as the sponsor conducting the trial.

Dr Fouad Namouni, head of development for oncology at Bristol-Myers Squibb, said: "Combination therapy with agents that target different and complementary pathways - in this case, the combination of a checkpoint inhibitor and innovative chemotherapy delivery - is a potential new approach for patients with difficult to treat cancers."

To date, the clinical development programme for Opdivo has enrolled more than 25,000 patients.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.